chartexchange

GANX
Gain Therapeutics, Inc. Common Stock
stockNASDAQ

Market OpenNov 17, 2026 12:02:10 PM EST
1.20USD+27.101%(+0.25)1,760,847
Pre-marketNov 17, 2026 9:25:30 AM EST
0.98USD+4.233%(+0.04)
0.9500Bid1.2800Ask0.3300Spread
Loading…
Loading…
Healthcare
Biotechnology
HQ
Bethesda, MD, USA
Previous Close
$0.94
Beta
1.75
52-Week High
$4.34 2025-12-11
52-Week Low
$0.94 2026-11-16
SMA 50
$1.45
SMA 200
$1.81
Avg. Vol 10D
383,429
Avg. Vol 30D
536,013
Avg. Vol 90D
508,100
Relative Vol
3.23
42.64M
1.2200%
5,043
GANX Profile

gain therapeutics is a preclinical stage biotech company specializing in the discovery of new drugs for orphan diseases. the company targets inborn errors of metabolism; a group of rare diseases of genetic origin with a high unmet medical need. gain therapeutics is also working on a new class of compounds: non-competitive pharmacological chaperones, identified through its innovative proprietary platform – see-tx. the gain therapeutics team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.

GANX Performance
PeriodPriceDateChangeBeta
1W1.082026-11-10+12.04%3.826
1M1.262026-10-16-3.97%2.130
3M2.042026-08-17-40.69%2.253
6M1.622026-05-18-25.31%2.323
1Y2.822025-11-17-57.09%1.746
2Y1.692024-11-18-28.40%—
5Y9.242021-11-17-86.91%1.149
GANX Stock Summary

Gain Therapeutics, Inc. Common Stock (NASDAQ:GANX) stock price today is $1.21, and today's volume is 1,729,444. GANX is up 28.696% today. The 30 day average volume is 536,013. GANX market cap is $53.88M with 44.53M shares outstanding.